PhRMA And Beijing-based RDPAC Call For Innovative Medicines To Support China’s Healthcare Reform

SHANGHAI - The Pharmaceutical Research and Manufacturers of America and the Beijing-based R&D Pharmaceutical Association Committee that represents Big Pharma in China, recently submitted a paper to the Chinese government to help the government better understand the role of innovative medicines in the ongoing healthcare reform in China